«Luteal Phase»
۲۶۶۵ نتیجهExpression of steroidogenic acute regulatory protein in the human corpus luteum throughout the luteal phase.
The expression of the steroidogenic acute regulatory protein (StAR) in the human corpus luteum (CL) was examined throughout the luteal phase. The primary 1.6-kb StAR transcript was in greater abundance in early (3.1-fold) and mid (2.2-fold) luteal phase CL compared with late lute
Expression of Aldo-keto Reductase 1C23 in the Equine Corpus Luteum in Different Luteal Phases
Regression of the corpus luteum (CL) is characterized by a decay in progesterone (P4) production (functional luteolysis) and disappearance of luteal tissues (structural luteolysis). In mares, structural luteolysis is thought to be caused by apoptosis of luteal cells, but function
Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
STUDY QUESTION Do differences in endometrial gene expression exist after ovarian stimulation with four different regimens of triggering final oocyte maturation and luteal phase support in the same patient? SUMMARY ANSWER Significant differences in the expression of genes involved
Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
STUDY QUESTION Can the luteal phase support be improved in terms of efficacy, hormonal profiles and convenience as compared with today's standard care? SUMMARY ANSWER Daily low-dose rhCG supplementation in GnRHa triggered IVF cycles can replace the traditional used luteal phase s
Gonadotropin and Sex Steroid Levels Across the Luteal Phase LH Plasma
A bstract. The pattern of episodic gonadotropin release was studied in 15 normal female volunteers during the luteal phase ofthe menstrual cycle with 24 h ofblood sampling for follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels at 10-min intervals. Six subjects
Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis
BACKGROUND The effects of gonadotrophin-releasing hormone agonist (GnRH-a) administered in the luteal phase remains controversial. This meta-analysis aimed to evaluate the effect of the administration of a single-dose of GnRH-a in the luteal phase on ICSI clinical outcomes. METHO
Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the know
The early luteal phase administration of estrogen and progesterone does not induce premature luteolysis in normo-ovulatory women.
OBJECTIVE The luteal phase after ovarian hyperstimulation for in vitro fertilization (IVF) is insufficient. Therefore, luteal phase supplementation is routinely applied in IVF. It may be postulated that premature luteolysis after ovarian hyperstimulation is due to supraphysiologi
Defense cells profile of cervical mucous during follicular and luteal phases of estrus cycle in river buffalo
The aim of this study was to evaluate the defense cells changes of cervical mucous during follicular and luteal phases of estrus cycle in river buffalo. Reproductive organs of the adult and apparently healthy female buffaloes were collected from the slaughterhouse. By visual inve
Luteal phase support in assisted reproduction
The first report of the combined use of pituitary suppression and ovarian hyperstimulation in invitro fertilization (IVF) and embryo transfer programmes was published in 1984 (1). Since then, the advantages of gonadotrophin hormonereleasing hormone analogues (GnRHa) have been wel